Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2009

View Archived Issues

Hydra raises financing to advance TRP ion channel programs

New serotonin reuptake inhibitors and 5-HT1A receptor antagonists discovered at Wyeth

Early phase II results show some activity with ARC-100 in pancreatic cancer patients

Roche discloses novel tachykinin NK3 receptor antagonists

Astellas Pharma divulges new prostanoid EP4 receptor agonists for PAD

New reverse transcriptase inhibitors for HIV presented in recent GSK patent

Bayer divulges new coagulation factor Xa and thrombin inhibitors for thromboembolic disorders

Auris Medical commences phase IIb AM-111 trial in hearing loss

FDA grants orphan drug status to omacetaxine for myelodysplastic syndromes

Oralair Grasses obtains pediatric marketing authorization in Germany

AGI completes patient enrollment in phase III study of Rezular in IBS-D

NexBio completes phase I clinical trial of influenza drug Fludase

Intercell plans to initiate a phase III clinical trial of TD vaccine in April 2009

Mesoblast initiates first human trial of stem cell treatment in knee osteoarthritis

Metabasis refocuses product pipeline as part of corporate restructuring

Bilastine as effective as desloratadine in seasonal allergic rhinitis

Antitumor activity increased with PLX-4032, capecitabine and bevacizumab in colorectal cancer model

Obecure completes enrollment in confirmatory phase IIb Histalean trial

Synergy seen with PARP-1 inhibitor BSI-401 and oxaliplatin in pancreatic cancer model

Nile to focus on development of CD-NP and CU-NP and terminate 2NTX-99 program

Cleveland completes dosing of fourth cohort in safety study of Protectan CBLB-502 for ARS

Abraxis plans to create Abraxis Health, focused on personalized medicine

Grifols obtains minority stake in Cardio3

RoActemra approved in the E.U. for rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...